Application of dsRNA in Cancer Immunotherapy: Current Status and Future Trends

Author(s): Bo Jin, Liu-Fang Cheng, Kai Wu, Xiao-Hong Yu, Anthony E.T. Yeo

Journal Name: Anti-Cancer Agents in Medicinal Chemistry
(Formerly Current Medicinal Chemistry - Anti-Cancer Agents)

Volume 14 , Issue 2 , 2014

Become EABM
Become Reviewer
Call for Editor


Cancer cells create a microenvironment that prevents tumor rejection by the host’s immune system. The activation of pattern recognition receptors (PRRs) can elicit an innate immune response and guide the adaptive immune response to overcome this. dsRNA analogs can trigger TLR3, RIG-I, MDA5, NLRP3 and several other PRRs to induce not only robust immune response against cancer but also programmed cell death. This review focuses on the signal pathways activated by dsRNA and examines examples of their clinical application in cancer treatment.

Keywords: Adjuvant, cancer vaccine, cross-presentation, cytokine, cytotoxic T lymphocyte, dendritic cell, double-stranded RNA, inflammasome, immune response, immunoediting, immunotherapy, melanoma differentiation-associated gene 5, nucleotide-binding domain and leucine-rich repeat containing gene family pyrin domain 3, polyadenylic-polyuridylic acid, polyinosinic-polycytidylic acid, poly (I:C12U), poly (ICLC), retinoic acid-inducible gene-I, T helper cell, toll-like receptor, tumor, tumor associated antigen.

Rights & PermissionsPrintExport Cite as

Article Details

Year: 2014
Published on: 28 January, 2014
Page: [241 - 255]
Pages: 15
DOI: 10.2174/18715206113136660373
Price: $65

Article Metrics

PDF: 52